Objective：To provide strong evidence for the rational use of antibiotics through investigating clinical distribution and drug resistance of 1 032 strains of extend-spectrum β-lactamases（ESBLs）-producing pathogenic bacteria. Methods：Clinical specimens were processed by laboratory methods for separation，cultivation and identification. Minimum inhibitory concentration（MIC） was used for antibiotic susceptibility tests. Both results of antibiotic resistance and ESBLs were assessed according to the operating standards developed by the United States National Clinical Laboratory Standards Committee. Results：There were 600 strains of Eschericha coli，302 strains of Klebsiella pneumoniae and 130 strains of Klebsiella oxytoca among the ESBLs-producing isolates. Eschericha coli showed high drug resistance to extended-spectrum penicillins，cephalosporins including the forthgeneration cephalosporin，single-ring lactams and part of aminoglycosides and the resistant rates were between 60% and 95%. While Klebsiella pneumoniae and Klebsiella oxytoca showed higher resistance to extended-spectrum penicillins and resistant rates were between 90% and 100%. Their resistance rates to cephalosporins were all above 40%. Conclusions：The ESBLs-producing pathogenic strains show high drug resistance. We should use antibiotics reasonably in order to control bacterial drug resistance and to prevent the wide prevalence of resistant strains.